(You can now subscribe to our(You can now subscribe to our ETMarkets WhatsApp channelThe fourth quarter results season is almost coming to a close, and as many as 895 companies will announce their earnings on Thursday.
The company will announce its results later in the evening.Net profit for the fourth quarter is likely to grow up to 68% year-on-year, according to various analyst estimates, while net sales are expected to rise 13% year-on-year.
We estimate a hospital EBITDA margin of 23.6%, 20bps quarter-on-quarter/-80bps year-on-year due to increased marketing and doctor costs," said Nuvama.With enhanced footfalls in primary care/Diagnostics and improved operational efficiencies, analysts also expect the company to register 15% and 37% year-on-year growth in Revenue and EBITDA (operating profit).
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own.
These do not represent the views of Economic Times)
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
The fourth quarter results season is almost coming to a close, and as many as 895 companies will announce their earnings on Thursday. Among such a massive mix, investors will watch out for earnings from Apollo Hospitals , which is expected to post a healthy improvement in earnings.Other companies which will also announce their earnings include Muthoot Finance TBO Tek , Authum Investment, Praj Industries, Rajesh Exports, Marksans Pharma and many more.Leading Hospital chain Apollo Hospitals is expected to post healthy growth in core earnings for the quarter ended March 2024 due to improved ARPOB (Average Revenue Per Occupied Bed) and Healthco operations. The company will announce its results later in the evening.Net profit for the fourth quarter is likely to grow up to 68% year-on-year, according to various analyst estimates, while net sales are expected to rise 13% year-on-year. Analysts are baking in an 11% year-on-year sales growth in the hospitals’ segment in 4QFY24, while HealthCo sales expected to grow 14% year-on-year, driven by growth in pharmacy distribution sales on account of the store expansion as well as traction in 24/7.Investors may watch out for the GMV outlook in Apollo 24/7 and updates on capacity expansions at Pune, Hyderabad, Kolkata and Bengaluru are the key monitorables."ARPOBs are also likely to remain steady at Rs 56,900. We estimate a hospital EBITDA margin of 23.6%, 20bps quarter-on-quarter/-80bps year-on-year due to increased marketing and doctor costs," said Nuvama.With enhanced footfalls in primary care/Diagnostics and improved operational efficiencies, analysts also expect the company to register 15% and 37% year-on-year growth in Revenue and EBITDA (operating profit).(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
